On Nov 05, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $5 to $12.
Barclays analyst Gena Wang maintains with a hold rating, and adjusts the target price from $7 to $5.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and adjusts the target price from $9 to $7.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
RBC Capital analyst Luca Issi maintains with a hold rating, and adjusts the target price from $8 to $5.
Raymond James analyst Steven Seedhouse downgrades to a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The recent quarterly update from Editas Medicine was seen as incremental after the company's strategic revision, an analyst noted to investors.
The emphasis by Editas Medicine on in vivo HSPC editing is viewed by analysts as a strategic utilization of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update slated for the first quarter of 2025, alongside developments on reni-cel BD activity.
The recent quarter is viewed as incremental following the strategic shift that was recently announced. Editas Medicine has shifted its focus towards partnering or out-licensing its leading asset for SCD/BT, centering attention on the in vivo pipeline. This move is deemed a sound strategy given the gradual adoption observed thus far for the class. Nevertheless, a position of watchfulness is maintained, pending additional advancements in the in vivo pipeline.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月5日，多家华尔街大行更新了$Editas Medicine (EDIT.US)$的评级，目标价介于5美元至12美元。
巴克莱银行分析师Gena Wang维持持有评级，并将目标价从7美元下调至5美元。
富国集团分析师Yanan Zhu维持买入评级，并将目标价从9美元下调至7美元。
TD Cowen分析师Phil Nadeau维持买入评级。
加皇资本市场分析师Luca Issi维持持有评级，并将目标价从8美元下调至5美元。
瑞杰金融分析师Steven Seedhouse下调至持有评级。
此外，综合报道，$Editas Medicine (EDIT.US)$近期主要分析师观点如下：
分析师指出，editas medicine最近的季度更新被视为在公司战略修订之后的渐进式调整。
editas medicine强调体内HSPC编辑，分析师认为这是其专业知识和资源的战略利用，以创造价值。人们对2025年第一季度即将到来的体内管道更新以及reni-cel BD活动的发展充满期待。
最近一个季度被视为在最近宣布的战略转变之后的渐进式调整。editas medicine已将重点转向与SCD/Bt的领先资产合作伙伴或外部许可，将注意力集中在体内管道上。考虑到迄今为止对该类别的逐渐采纳，这一举措被视为明智的策略。然而，在体内管道的进一步发展方面仍保持谨慎，
以下为今日6位分析师对$Editas Medicine (EDIT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
